The AKT-modified expression has been implicated in various cancers, including esophageal and colon cancer, and is also associated with cell growth, apoptosis or epithelial–mesenchymal transition (EMT) during the process of carcinogenesis.6,7 EGFRvIII and phosphorylated AKT are considered as predictive value for patient survival outcome.8 Several studies have reported that the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is involved in oral cancer progression and the AKT signaling pathway may be an important therapeutic target of oral cancer.8-11. This evidence concerns the gene MTOR and malignant colon neoplasm.